Population studies support an increased incidence of most cancers among older adults.
Colorectal cancer has high prevalence in the aging population, with a median age of 69 …

Background There is an unmet need for predictive markers for the antiangiogenic agent
bevacizumab in metastatic colorectal cancer (mCRC). We aimed to assess whether the …

Simple Summary The liver is a common site of metastasis across multiple solid organ
malignancies. Liver metastases are a known site of treatment resistance, regardless of the …

The progressively ageing population combined with an increased availability of antitumoural
agents has created a new, challenging therapeutic scenario for oncologists. Due to the lack …

Colorectal cancer (CRC) is the most common malignant tumor in Western countries. Despite
efforts made to implement screening programmes for early detection and treatment, still half …

Bevacizumab improves survival when added to chemotherapy in metastatic colorectal
cancer (mCRC). We assessed the safety and efficacy of bevacizumab in mCRC patients≥ …

Background Colorectal cancer (CRC) is one of the most commonly diagnosed cancers
globally in both men and women. Based on the most recent global cancer statistics, an …

Aim: Capecitabine, designed as a pro-drug to the cytotoxic agent 5-fluorouracil, is widely
used in the management of colorectal cancer. This study was designed to investigate …

The past decade has seen unprecedented advancements in our ability to treat patients with
metastatic colorectal cancer. When applying these advances—hepatic resection and multi …

Colorectal cancer (CRC) is a significant health problem, with around 1 million new cases
and 500000 deaths every year worldwide. Over the last two decades, the use of novel …